Evidence map›Paper›PMID 42826833›Full record

ArticleCancer letters2026

Targeting p300/CBP destabilizes HIF-2α and suppresses tumor growth in cell and animal models of clear cell renal cell carcinoma.

Rushaniya Fazliyeva, Alexey Matveev, Ruslan Smetanin, Ilia Fedorov, Kathy Q Cai, Alexander Kutikov, Robert G Uzzo, Andrew Andrews, Peter Makhov, Vladimir M Kolenko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rushaniya FazliyevaCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Alexey MatveevCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Ruslan SmetaninCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Ilia FedorovCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Kathy Q CaiHistopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Alexander KutikovDepartment of Urology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Robert G UzzoDepartment of Urology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Andrew AndrewsChemistry and Biochemistry Department, College of Science and Engineering, University of North Carolina Wilmington, Wilmington, NC, 28403, USA.
Peter MakhovCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Vladimir M KolenkoCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Electronic address: Vladimir.Kolenko@fccc.edu.

Funding

NPC1 as a novel therapeutic target in ccRCCR21CA289161 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI KOLENKO, VLADIMIR M · 2024 to 2025
$483k
Targeting p300/CBP in renal cell carcinomaR21CA296705 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI KOLENKO, VLADIMIR M · 2025 to 2025
$483k
Targeting the Undruggable in Castration-Resistant Prostate Cancer with FTDR-Stapled Peptide ProbesR03CA304040 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI KOLENKO, VLADIMIR M, WANG, ROSS · 2025 to 2025
$177k
NCI NIH HHS R03 CA304040NCI NIH HHS R21 CA289161NCI NIH HHS R21 CA296705
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42826833
PMCPMC13689529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.